1. 4-amino-1-hydroxybutylidene 1,1-biphosphonate
2. Alendronate
3. Alendronate Monosodium Salt, Trihydrate
4. Aminohydroxybutane Bisphosphonate
5. Fosamax
6. Mk 217
7. Mk-217
8. Mk217
1. 129318-43-0
2. Fosamax
3. Binosto
4. Fosamac
5. Onclast
6. Monosodium Alendronate
7. Alendronate Sodium Anhydrous
8. Alendronate Monosodium
9. Mk 217
10. Alendronic Acid Monosodium Salt
11. Mk-217
12. Sodium;(4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate
13. Adrovance
14. Fosavance
15. G-704650
16. Vantavo
17. Onclast; Osteovan; Sodium Alendronate
18. 4988k7x26p
19. Osteovan
20. Indrol
21. Alend
22. Neobon
23. Alendronate (as Sodium)
24. Phosphonic Acid, (4-amino-1-hydroxybutylidene)bis-, Monosodium Salt
25. Nsc-722597
26. Nsc-758931
27. Almerol
28. Avalent
29. Bonalon
30. Steovess
31. Teiroc
32. Unii-4988k7x26p
33. Ahbutbp
34. Ahbubp
35. (4-amino-1-hydroxybutylidene)bisphosphonic Acid Monosodium Salt
36. Chembl675
37. Alendronic Acid Sodium Salt
38. Gth-42j
39. Gth-42v
40. Gth-42w
41. Schembl328770
42. Gth-42
43. Dtxsid70904501
44. Mer-103
45. Hms3604i12
46. Hms3713p04
47. Sodium Alendronate Anhydrous
48. Bcp28464
49. Alendronic Acid, Sodium Aldendronate
50. Bdbm50247920
51. Ex-101
52. Mfcd01861681
53. Akos015895071
54. Ccg-220631
55. Ks-1028
56. Mk-0217
57. Hy-108685
58. Cs-0029477
59. Mk 217;mk-217;mk217;sodium Alendronate
60. A805927
61. J-005667
62. L-670452
63. Q27259256
64. Monosodium (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate
65. Sodium Hydrogen-4-amino-1-hydroxy-1-phosphonobutylphosphonate
66. (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic Acid Monosodium Salt
67. 4-amino-1-hydroxybutylidene-1,1-bisphosphonic Acid Monosodium Salt
68. P,p'-(4-amino-1-hydroxybutylidene)bis-phosphonic Acid Monosodium Salt
69. Phosphonic Acid, P,p'-(4-amino-1-hydroxybutylidene)bis-, Sodium Salt (1:1)
Molecular Weight | 271.08 g/mol |
---|---|
Molecular Formula | C4H12NNaO7P2 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 270.99867000 g/mol |
Monoisotopic Mass | 270.99867000 g/mol |
Topological Polar Surface Area | 164 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 293 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Alendronate sodium |
PubMed Health | Alendronate (By mouth) |
Drug Classes | Calcium Regulator |
Drug Label | FOSAMAX1 (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.Alendronate sodium is che... |
Active Ingredient | Alendronate sodium |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 40mg base; eq 5mg base; eq 70mg base; eq 10mg base; eq 35mg base; eq 70mg base/75ml |
Market Status | Prescription |
Company | Watson Labs; Teva Pharms; Austarpharma; Apotex; Aurobindo Pharma; Cadista Pharms; Dr Reddys Labs; Cipla; Sun Pharma Global; Mylan; Roxane |
2 of 6 | |
---|---|
Drug Name | Binosto |
Drug Label | BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.Alendronate sodium is chem... |
Active Ingredient | Alendronate sodium |
Dosage Form | Tablet, effervescent |
Route | Oral |
Strength | eq 70mg base |
Market Status | Prescription |
Company | Mission Pharma |
3 of 6 | |
---|---|
Drug Name | Fosamax |
PubMed Health | Alendronate (By mouth) |
Drug Classes | Calcium Regulator |
Drug Label | FOSAMAX1 (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.Alendronate sodium is che... |
Active Ingredient | Alendronate sodium |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 70mg base; eq 70mg base/75ml |
Market Status | Prescription |
Company | Merck; Merck And |
4 of 6 | |
---|---|
Drug Name | Alendronate sodium |
PubMed Health | Alendronate (By mouth) |
Drug Classes | Calcium Regulator |
Drug Label | FOSAMAX1 (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.Alendronate sodium is che... |
Active Ingredient | Alendronate sodium |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 40mg base; eq 5mg base; eq 70mg base; eq 10mg base; eq 35mg base; eq 70mg base/75ml |
Market Status | Prescription |
Company | Watson Labs; Teva Pharms; Austarpharma; Apotex; Aurobindo Pharma; Cadista Pharms; Dr Reddys Labs; Cipla; Sun Pharma Global; Mylan; Roxane |
5 of 6 | |
---|---|
Drug Name | Binosto |
Drug Label | BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.Alendronate sodium is chem... |
Active Ingredient | Alendronate sodium |
Dosage Form | Tablet, effervescent |
Route | Oral |
Strength | eq 70mg base |
Market Status | Prescription |
Company | Mission Pharma |
6 of 6 | |
---|---|
Drug Name | Fosamax |
PubMed Health | Alendronate (By mouth) |
Drug Classes | Calcium Regulator |
Drug Label | FOSAMAX1 (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.Alendronate sodium is che... |
Active Ingredient | Alendronate sodium |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 70mg base; eq 70mg base/75ml |
Market Status | Prescription |
Company | Merck; Merck And |
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.
Adrovance reduces the risk of vertebral and hip fractures.
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.
Fosavance reduces the risk of vertebral and hip fractures.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
M05BB03
M05BB03
LOOKING FOR A SUPPLIER?